There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.